Jazz Pharmaceuticals plc
Modeyso
sleep neuro-oncology
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for Modeyso in sleep neuro-oncology are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Modeyso approval granted ahead of schedule • Enrollment ongoing and on track; interim OS data • Strong early launch performance with nearly late 2026 / early 2027 $50M in revenue for 20251 • Potential ex-U.S. expansion opportunities • Futur”